November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty
Jul 17, 2023, 09:59

Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC – Debyani Chakravarty

My OncoKB people: Zenocutuzumab has rec’d Breakthrough Designation (BTD) from US FDA for NRG1+ NSCLC.

Looking fwd to it getting tumor agnostic approval based on Alison Schram work showing 42% ORR in PDAC (& 35% in NSCLC).

 

Source: Debyani Chakravarty / Twitter